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1. Introduction 
1.1 Current clinical situation and medical treatment options for ACC 
Adrenocortical carcinoma (ACC) is a very rare but highly heterogeneous malignancy with an 
annual incidence of 0.7 to 2.0 cases per million [1]. This tumor entity is characterized by a very 
aggressive clinical behavior [2] and reveals a bimodal age distribution pattern with peaks in early 
childhood as well as in the fourth and fifth decade of life [3, 4].  
 
In patients without clinical symptoms of hormone hypersecretion, local tumor progression and 
spreading into the surrounding viscera often lead to unspecific symptoms as back pain, 
abdominal discomfort as well as nausea and vomiting [4]. However, in approximately 60% of 
cases patients display symptoms with evidence of adrenal steroid hormone excess most 
frequently presented as rapid progressing Cushing’s syndrome with or without virilization due to 
excessive androgen production [3, 4]. Such patterns of abnormal hormonal secretion can be 
highly variable depending on tumor size, stage and differentiation which leads to delayed 
diagnosis as syndromes of hormonal excess are often not easily recognized [4]. Thus, advanced 
ACC defined as tumor stage III (in the case of local tumor spread) or as stage IV (in the 
presence of distant metastases), represent 18-26% and 21-46% of adrenocortical tumors at 
diagnosis, respectively [2]. The individual tumor stage at initial diagnosis, very recently updated 
by the modified ENSAT (mENSAT) classification, is one of the keystones for prognostic 
stratification [2]. As such, also the number of organs affected by the tumor and the involved 
lymph nodes have important prognostic value [2].  
 
The prognosis for ACC revealing an advanced tumor stage III and IV at diagnosis is dismal with 
a 5-year overall survival of 50% and 2%, respectively [2]. Furthermore, there is a strong 
tendency towards rapid progression in advanced ACC while disease stabilization for longer than 
three months is rarely observed [1]. Currently, a complete tumor resection represents the only 
curative approach for localized adrenocortical tumors and therapeutic intervention must be 
considered to be palliative in case of unresectable or metastatic tumors [5]. Although the 
majority of ACC is surgically resectable at presentation, up to 85% of tumors relapse after 
radical resection [6] as the high growth potential of this endocrine neoplasm in many cases leads 
to already advanced metastasized tumors at initial ACC diagnosis [4, 7].  
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Medical therapy of locally advanced or metastasized ACC is limited to common cytostatic drugs 
which are usually combined with mitotane (o,p’DDD, 1,1-dichloro-2(o-chlorophenyl)-2-(p-
chlorophenyl)ethane), a substance exhibiting adrenolytic effects [4, 5, 8]. Of pivotal importance 
for the management of this rare disease was the first international randomized trial in locally 
advanced adrenocortical carcinoma treatment (FIRM-ACT [9], Fig. 1). 
Fig. 1: Progression-free survival during first-line therapy with streptozotocin (Sz) and mitotane (M) versus 
etoposide, doxorubicin and cisplatin (EDP) plus mitotane (M) (adapted from [9]). 
  
For the first time, the two most promising therapy regimens for advanced ACC were compared in 
a large cohort of patients: Streptozotocin and mitotane (Sz-M) versus etoposide, doxorubicin and 
cisplatin plus mitotane (EDP-M) [9]. Compared to Sz-M, the EDP-M combination chemotherapy 
protocol led to higher response rates and longer progression-free survival (Fig. 1) [9]. In 
accordance with this clinical trial, EDP-M was defined as the current treatment standard for 
advanced and metastasized ACC [9]. Nevertheless, this prospective trial also clearly evidenced 
that the therapeutic efficacy of EDP-M treatment is still poor and very unsatisfactory (Fig. 1). 
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Moreover, the combined administration of potent cytostatic drugs together with mitotane results 
in a highly toxic regimen with severe dose-limiting side-effects. As shown in figure 2, treatment 
with EDP-M leads to severe off-target actions. Such adverse effects are characterized by 
hematological toxicities with dose-limiting leucopenia, gastrointestinal and other toxicities which 
also include irreversible cardiotoxic and nephrotoxic events [9, 10].  
Fig. 2: Adverse effects of streptozotocin (Sz) and mitotane (M) versus etoposide, doxorubicin and cisplatin 
(EDP) plus mitotane (M) which were both investigated in the FIRM-ACT study (adapted from [9]). 
  
In particular, the cytostatic drug doxorubicin is well known to induce congestive heart failure as 
well as cardiomyopathy even many years after treatment [11, 12]. Thus, the cumulative dose of 
doxorubicin has to be limited in clinical practice. This fact creates a dilemma of balancing 
suboptimal oncologic therapy with a proven beneficial treatment against the risk of inducing 
irreversible cardiotoxic effects [11]. Also, the significant risk of cisplatin-induced nephrotoxicity 
impedes the use of higher doses of cisplatin to maximize its anti-tumoral effects in therapeutic 
treatment regimens [13]. The decisive and most important objective of novel therapeutic 
approaches for advanced ACC thus consists of developing treatment regimens with reduced off-
target profiles while maintaining or even increasing therapeutic efficacy. 
 14 
1.2 Liposomal chemotherapies 
In recent years, liposomal chemotherapies have been established to improve off-target profiles 
as well as therapeutic efficacy. Compared to their conventional free formulation, liposomal drugs 
have slower releasing rates and sustained bioavailability [14, 15]. Moreover, liposomes can be 
grafted using the biocompatible polymer polyethylene glycol (PEG) which is inert and forms a 
protective layer on the surface (see Fig. 3) [16, 17]. Such modification using PEG prevents 
recognition of liposomes by opsonins and leads to a reduced clearance by the 
reticuloendothelial system (RES) [16]. 
Fig. 3: Cross-sectional view of a PEGylated (polyethylene glycol) liposomal formulation of doxorubicin 
(doxil®, caelyxTM). Polymer groups of polyethylene glycol form a protective layer on the liposome surface 
and provide additional stability, HSPC = hydrogenated soy phosphatidylcholine (adapted from [17]).  
 
These so-called “sterically stabilized liposomes” reveal an increased half-life in the plasma 
compartment [18]. Using modifications as PEGylated phospholipids, an extension of the terminal 
half-life of such long-circulating liposomes from a time-scale of minutes to days has been 
demonstrated [16, 19]. Small-molecule properties of most conventional chemotherapeutic 
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agents lead to a high volume of distribution and thereby to significant toxicity for normal tissues 
as well as low drug levels at the tumor site. Such biodistribution patterns are modified by 
liposomal encapsulation which leads to decreased volumes of distribution of cytotoxic drugs and 
improved delivery to the site of action [17, 19]. 
Fig. 4: Passive tumor targeting of long-circulating liposomal cytostatic drugs occurs by the enhanced 
permeability and retention (EPR) effect. The angiogenic vasculature in the tumor site is hyperpermeable 
and enables a preferential extravasion of macromolecular liposomal cytostatic drugs (adapted from [20]).  
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In particular, a passage through the two nanometer pores of the blood vessel endothelium in 
most healthy tissues or through the six nanometer gaps of postcapillary venules is prevented as 
liposomal carriers are characterized by a relatively large size of 45-150 nanometers [15]. 
However, during angiogenesis solid tumors develop a discontinuous endothelium characterized 
by large fenestrations allowing molecules to enter the interstitial space [19]. Moreover, once 
liposomes have entered the tumor tissue, they are retained from the malfunctioning lymphatic 
system and after its release the drug can exert its therapeutic effect [18, 19]. This phenomenon 
was termed the “tumor-selective enhanced permeability and retention (EPR) effect” or “passive 
tumor targeting effect” and has been studied in detail (see Fig. 4 and 5) [16, 17, 21]. Taken 
together, the therapeutic index of a cytostatic drug encapsulated in liposomes is increased by 
two main mechanisms: firstly, improved tolerability by a decrease in volume of distribution in the 
body and secondly, increased anti-tumoral efficacy by passive tumor targeting.  
 
An excellent example for a successful clinical translation is liposomal doxorubicin, which 
improved the therapeutic index of doxorubicin while dose-limiting cardiotoxicity was significantly 
reduced [14, 19]. Approved formulations of liposomal doxorubicin (myocetTM, caelyxTM and 
doxilTM, lipo-doxTM) are available for different tumor entities as Kaposi’s sarcoma, ovarian cancer, 
multiple myeloma as well as for metastatic breast cancer in Europe [22]. A significant reduction 
of nephrotoxicity has been demonstrated for a PEGylated liposomal formulation of cisplatin 
(lipoplatinTM) which overcomes the significant risk of the dose-limiting adverse effect induced by 
conventional cisplatin [13]. LipoplatinTM is currently evaluated for the treatment of non-small cell 
lung cancer in phase III trials and in 2007 it received “orphan drug” status as first line-treatment 
for pancreatic cancer in an ongoing Phase II/III trial [13, 23-25].  
 
In the classical EDP-M regime, conventional formulations of the cytostatic drugs doxorubicin, 
cisplatin and etoposide are administered [9]. In recent years, it has been demonstrated that 
liposomal encapsulation of doxorubicin and cisplatin represents an important strategy to improve 
the properties of the parental drugs. Liposomal formulations of etoposide have not yet reached 
clinical trials status investigations. However, several preclinical in vitro and in vivo studies have 
revealed improved off-target profiles together with enhanced anti-tumoral efficacy [26].  
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1.3 Liposomal chemotherapeutic protocols as novel therapeutic approaches for ACC 
In addition to the outlined general advantages of liposomally modified chemotherapies, in 2012 
Hantel et al. were able to a provide evidence for an extraordinary uptake phenomenon and 
internalization of liposomes specifically for adrenocortical cell lines (see Fig. 6) [27-29].  
 
While the exact mechanism for this enhanced uptake of liposomes in adrenocortical tumor cells 
remains uncertain [27], this observation has clearly provided evidence for an additional potential 
role for liposomal chemotherapies in the treatment of ACC. Furthermore, the working group of 
Hantel et al. detected significant therapeutic efficacy of liposomal doxorubicin (caelyxTM) in 
preclinical experiments utilizing a xenograft model for ACC [27].  
Fig 6: Cellular association of plain liposomes in different tumor cell lines BON (gastroenteropancreatic 
neuroendocrine tumors), Kelly (neuroblastoma), DU145 (prostate cancer), NCI-H295R and SW-13 (both 
models utilized for adrenocortical carcinoma) indicating a relevant uptake only in the adrenocortical cell 
lines (adapted from [27]). Stars denote significant differences; ***, p<0.001. 
 
Following these observations a liposomal variant of the classical EDP-M scheme referred to as 
“LEDP-M” was established [28]. This treatment scheme LEDP-M is composed of etoposide, 
liposomal doxorubicin, liposomal cisplatin and mitotane and was investigated in xenograft 
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models for ACC [28]. In this study, long-term experimental settings provided evidence for a 
sustained and highly significant anti-tumoral efficacy of LEDP-M compared to the classical EDP-
M protocol (see Fig. 7).  
Fig 7: Tumor development in NCI-H295R tumor bearing mice upon different treatments including the 
therapeutic treatment protocols EDP-M and LEDP-M (adapted from [28]). In this experiment, also other 
therapeutic regimen PDP-M (cisplatin, doxorubicin, paclitaxel) and LPDP-M (liposomal cisplatin, liposomal 
doxorubicin, albumin-bound paclitaxel) were investigated. Stars depicted in the figure denote significant 
differences to EDP-M; *, p<0.05; **, p<0.01 and ***, p<0.001 [28]. 
 
The outcome and results of this preclinical study indicated that LEDP-M may represent an 
interesting option for the therapy of adrenocortical tumors [28]. Nevertheless, preclinical testing 
of novel therapeutic approaches for ACC is generally limited in clinical prediction as only one 
standardized xenograft model for ACC was available at the time. 
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1.4 Human xenograft models of ACC 
In addition to the development of novel therapeutic approaches appropriate preclinical tumor 
models are an essential and indispensable tool to proceed from preclinical testing to clinical trial 
status [30]. The situation is aggravated for ACC by the fact that the availability of human tumor 
models for ACC is very limited. Moreover, varied clinical presentation of patients with great 
differences in ACC biological behavior (for example high versus low or no functional activity) 
indicates the high heterogeneity of ACC [9, 10]. Consequently, this poses a major obstacle in 
finding appropriate and reliable preclinical in vivo models for ACC [30].  
 
The most commonly used adrenocortical tumor model of human origin is NCI-H295R [30, 31]. 
This ACC cell line retained histological parameters compared with the original patient tumor from 
which the cell line was derived. NCI-H295R cells have furthermore shown to produce all major 
adrenal steroids [31]. NCI-H295R tumor cells can also be injected as subcutaneous tumor cell 
suspension in immunodeficient nude mice and a successful tumor development has been 
reported in about 90% of injected nude mice [32].  
 
Another tumor model, SW-13, has been utilized in recent years for non-active ACC [33]. This 
tumor model contributed, for instance, to the demonstration of the importance of angiogenic 
pathways in ACC by studying the anti-tumoral effects of vascular endothelial growth factor 
receptor (VEGFR) tyrosine kinase inhibitors [34]. Furthermore, nanotechnologically modified 
albumin-bound paclitaxel was identified as a potential active substance for the treatment of ACC 
[35]. However, SW-13 does not originate from a primary adrenocortical carcinoma as it was 
established from a non-secreting small-cell carcinoma in the adrenal cortex [33]. Nevertheless, 
as other human tumor models for non-functional ACC were not available, SW-13 was widely 
accepted to be used for such studies in recent years.  
 
Even though such cell line based tumor models can be utilized to establish tumor xenografts in 
immunodeficient mice, these tumors still originate from cell suspensions. Selection processes 
during high numbers of cell culture passages are very likely to lead to modified biologic 
properties and altered cell clone characteristics [30, 36]. Thus, resulting tumor xenografts might 
no longer reflect alterations in functional properties or specific therapeutic responses of the 
original patient tumor [36, 37]. In 2013, Pinto et al. established and characterized with SJ-ACC3 
the first pediatric but also the first tissue-based tumor model for adrenocortical carcinoma [38]. 
Compared to the tumor models NCI-H295R and SW-13 which originate from cell lines, this 
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xenograft model is based on subcutaneous implantation of original patient tumor tissue. 
Originating from a pediatric patient tumor with endocrine functionality, the SJ-ACC3 xenograft 
model maintained the histopathologic and molecular features of the primary tumor [38]. Only 
recently, another successful re-implantation of cryoconserved SJ-ACC tumor pieces and 
subsequent therapeutic implementation of this tumor model was reported demonstrating its wide 
applicability in ACC research [39]. However, no cell line for complementing additional in vitro 
experiments could be established for SJ-ACC3 limiting the applicability of this tumor model.  
 
Very recently, another patient-derived xenograft model, referred to as MUC-1, was established 
by subcutaneous implantation of a surgical tumor specimen. Moreover, also a human tumor cell 
line was established originating from MUC-1 xenografts [30, 39]. Consequently, the MUC-1 
tumor model represents the only available human cell-line and tissue based xenograft model for 
ACC [30, 39] and is, thus, thought to further improve preclinical experiments in the future.  
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1.5 Circulating micro-RNAs as marker for therapeutic efficacy in ACC 
Not only effective therapeutic strategies but also prognostic markers and indicators of treatment 
response are absolutely essential to improve the diagnosis and outcome of ACC therapy. Micro-
RNA (miR) are defined as small non-coding RNA molecules which are important regulators for 
gene expression [40]. This characteristic feature promotes their role as important regulators for 
physiological, pathological settings and tumorigenesis [41]. Specific signatures of aberrant miR 
expression patterns have been demonstrated for a variety of malignancies including ACC [42, 
43].  
 
Novel findings have proven the existence of miR in body fluids as plasma samples and several 
circulating miR have been associated with different types of cancer [40]. Even if the source of 
circulating miR remains not fully understood [42], many miRs reveal similar expression changes 
in blood samples and tissues in various types of cancer [40, 43]. In accordance, correlations of 
circulating miRs in blood samples with cancer progression, therapy response and outcome of 
survival have been described [40, 43]. Such novel approaches provide evidence that miR have 
great potential to be used as minimal invasive biomarkers to monitor therapeutic responses 
upon anti-tumoral treatment [43]. In relation to ACC, plasma samples of patients have recently 
been analyzed for candidate miR as several miRs have been reported to be differentially 
expressed in adrenocortical adenoma or carcinoma tissues [42]. This study [42] revealed for 
miR-483-5p and miR-210, amongst others, elevated levels in plasma samples of ACC patients 
compared to adenoma samples.  
 
MiR-483-5p represents one of the most investigated miR in adrenocortical tumors as it is 
transcribed from an intronic sequence of the insulin-like growth factor 2 (IGF2) gene [42]. This 
gene has been found to be overexpressed in ACC and was shown to significantly correlate with 
IGF2 mRNA located in ACC tissue samples [42]. Moreover, elevated miR-483-5p expression 
has also been identified in a subgroup of patients with significantly poorer prognosis [43-45].  
 
MiR-210 has been reported to be overexpressed in a variety of tumor entities including breast, 
lung and pancreatic cancer [46-49]. Several publications have revealed that hypoxia-inducible 
factor 1α (HIF1α) is an important regulator for miR-210 expression [50]. HIF1α represents an 
important regulatory factor overexpressed in a variety of tumors [50]. MiR-210 is referred to as 
the master hypoxamir and micromanager of the hypoxia pathway and is also known to be 
involved in cell cycle regulation, mitochondrial metabolism, DNA repair mechanisms and 
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angiogenesis [50, 51]. High miR-210 levels in ACC tumors have been furthermore shown to 
correlate with clinicopathological parameters of aggressiveness as well as poor prognosis [44]. 
Thus, intratumoral and especially circulating miR-210 and miR-483-5p levels represent 
interesting candidates for the development of novel ACC biomarkers. 
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1.6 General aim 
Liposomal formulations of two out of three substances of the classical clinical EDP-M protocol 
are already in clinical use for other tumor entities highlighting the potential for a liposomal EDP-
M regime. Thus, the development and application of liposomal chemotherapeutic regimens 
represent a promising innovative approach to develop novel treatment options for advanced 
adrenocortical tumors.  
 
Therefore, the three main objectives of this project were: 
 
1. The investigation of a classical EDP-M and the novel liposomal LEDP-M regimen in two 
xenograft models representing clinically relevant patient heterogeneity: SW-13 
(hormonally inactive tumors) and SJ-ACC3 (pediatric tumors). 
 
2. The establishment of a liposomal treatment scheme including also a liposomal 
formulation of etoposide (referred to as treatment arm L(l)EDP-M).  
 
3. The investigation of intratumoral and circulating microRNA-210 and microRNA-453-5p 
levels upon therapeutic intervention to assess a putative applicability as therapeutic 
biomarkers for ACC. 
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2. Materials and Methods 
2.1 Reagents and equipment 
Tab. 1: General laboratory equipment 
Material Product specification Company 
   
Aqua distilled 7381901 Medizinische Klinik und Poliklinik IV, 
Munich, Germany 
Bright-field microscope DMRB Leica Microsystems, Wetzlar, Germany 
Bright-field microscope Zeiss IM35 Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
Centrifuge Eppendorf 5415D Eppendorf, Wesseling-Berzdorf, Germany 
Centrifuge Hettrich Ultra 2S Hettrich, Tuttlingen, Germany 
Ethanol 15091748 Medizinische Klinik und Poliklinik IV, 
Munich, Germany 
Falcon Tubes (50 ml) 62547254 Sarstedt, Nürmbrecht, Germany 
Laboratory scale BP 121 S Sartorius, Göttingen, Germany 
Laminar airflow bank - Heraeus, Hanau, Germany 
Oven Function Line Heraeus, Hanau, Germany 
Pipet tips (10-1000 µl) 701116200 
70760211 
70762200 
Sarstedt, Nümbrecht, Germany 
Pipets (10-1000 µl) P10-P1000 Gilson, Villiers-le-Bel, France 
Plate shaker mini rocker L024 Kisker, Steinfurt, Germany 
Safelock Eppendorf tubes T9661, T2795 Sigma-Aldrich, Steinheim, Germany 
Scale EMB 220-1 Kern&Sohn, Balingen, Germany 
Vortexer Vortex-Genie SI-0136 Scientific Industries, Springfield, MA, USA 
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Tab. 2: Reagents and equipment for immunohistochemistry 
Material Product 
specification 
Company 
   
Acetic acid  137000 Merck-Millipore, Darmstadt, Germany 
Bovine serum albumin  5482 Sigma-Aldrich, Steinheim, Germany 
Citric acid 251275 Sigma-Aldrich, Steinheim, Germany 
Cover glasses 48393-070 VWR GmbH, Darmstadt, Germany 
DAB (3,3’-diaminobenzidine) D4293 Sigma-Aldrich, Steinheim, Germany 
DeadEnd Colorimetric 
TUNEL Kit 
G7130 Promega GmbH, Mannheim, Germany 
Embedding cassettes 
simport 
M491-11 
7-0010 
Bernard-Pilon, Beloeil Quebec, Canada 
Eosin Y solution HT110232 Sigma-Aldrich, Steinheim, Germany 
Goat serum 31876 Jackson Immuno Research, PA, USA 
Hematoxylin Harris’ HHS32 Sigma-Aldrich, Steinheim, Germany 
Hydrogen peroxide (H2O2) 107298 Merck-Millipore, Darmstadt, Germany 
Ki67 primary antibody KI68R06 DCS innovative diagnostics, Hamburg, 
Germany 
Ki67 secondary goat anti-
rabbit biotinylated IgG 
BA-1000 Vector Laboratories, Burlingame, CA, USA 
Liquid Blocker Super 
PapPen 
MKP-1 Kisker, Steinfurt, Germany 
Methanol 106009 Merck-Millipore, Darmstadt, Germany 
Microtome HM 355 E Microm, Walldorf, Germany 
Microwave LCS1112SW LG Electronics Deutschland GmbH, 
Ratingen, Germany 
Paraffin 107337 Merck-Millipore, Darmstadt, Germany 
Paraffin bath SB 80 Microm, Walldorf, Germany 
Paraformaldehyde (PFA) P6148 Sigma-Aldrich, Steinheim, Germany 
Permount mounting medium SP15-500 Fisher Scientific, Fair Lawn, NJ, USA 
Phosphate Buffered Saline 
(PBS) Pellets 
P4417 Sigma-Aldrich, Steinheim, Germany 
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Material Product 
specification 
Company 
   
Slides (superfrost plus) J1800AMNZ Menzel GmbH, Braunschweig, Germany 
Sodium citrate 1613859 Sigma-Aldrich, St. Louis, MO, USA 
Tissue processor STP 120 Microm, Walldorf, Germany 
Tween 20 P1379 Sigma-Aldrich, Steinheim, Germany 
VectaMount AQ Mounting 
Medium 
H-5501 Vector Laboratories, Burlingame, CA, USA 
Vectastain Elite ABC Kit PK-6100 Vector Laboratories, Burlingame, CA, USA 
Vector Methyl Green   H-3402 Vector Laboratories, Burlingame, CA, USA 
Xylene 108661 Merck-Millipore, Darmstadt, Germany 
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Tab. 3: Reagents and equipment for cell culture 
Material Product 
specification 
Company 
   
Cell culture flasks, 225 cm² 353138 Falcon, BD biosciences, Heidelberg, 
Germany 
DMEM/F12 31330-095 Gibco Invitrogen, Darmstadt, Germany 
Dulbecco’s Phosphate 
Buffered Saline (PBS) sterile 
14190-094 Gibco Invitrogen, Darmstadt, Germany 
Fetal bovine serum (FBS) 10500064 Gibco Invitrogen, Darmstadt, Germany 
Incubator Hera cell 150 Heraeus, Hanau, Germany 
Insulin-Transferrin-Selenium 
supplement 
41400-045 Gibco Invitrogen, Darmstadt, Germany 
Medium 199 2350-029 Gibco Invitrogen, Darmstadt, Germany 
Neubauer counting chamber 
(Neubauer improved) 
0,0025 mm², 
0,100 mm 
PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
Penicillin/Streptomycin (P/S) 15140-122 Gibco Invitrogen, Darmstadt, Germany 
Trypan blue solution 15250-061 Gibco Invitrogen, Darmstadt, Germany 
Trypsin-EDTA 0,05% 25300-054 Gibco Invitrogen, Darmstadt, Germany 
UltroserG 15950-017 CytoGen GmbH, Sinn, Germany 
 
 
 28 
Tab. 4: Reagents and equipment for animal experiments 
Material Product 
specification 
Company 
   
Animals 
(female, 6–8 weeks old) 
Athymic NMRI nu/nu 
mice  
Harlan Winkelmann, Borchen, Germany 
Antisedan (Alzane) 45655R-0512 Pfizer GmbH, Berlin, Germany 
Domitor (Dorbene)  45081R-0313 Pfizer GmbH, Berlin, Germany 
Isoflurane (Forene) 05260-05 Abbott GmbH, Wiesbaden, Germany 
Isoflurane vaporizer UnivetPorta 
Narkosesystem 
Groppler Medizintechnik, Düsseldorf, 
Germany 
Isopropanol 100995 Merck-Millipore, Darmstadt, Germany 
Ketamin (Ketavet) PZN 7506004 Pfizer GmbH, Berlin, Germany 
Microvettes (EDTA) 200K3E Sarstedt, Nürmbrecht, Germany 
Novalgin (Novalminsulfon) N95362.14 Ratiopharm GmbH, Ulm, Germany 
Permanent marker 3000 Edding Vertrieb GmbH, Wunstorf, 
Germany 
Protective clothing - Zentrale Versuchstierhaltung, Kliniken 
Innenstadt, Munich, Germany 
Restrainer Type Broome HAR-
52-04 
Föhr Medical Instruments GmbH, 
Seeheim/Ober-Beerbach, Germany 
Scalpel 0200130010 PFM medical AG, Cologne, Germany 
Sodium chloride 0,9% (NaCl) 
sterile 
5122110950411 Braun AG, Melsungen, Germany 
Surgical equipment (forceps, 
scissors, thread holder) 
HSB 391-10 
HSC 011-04 
HWC-075-13 
HSE-028-142 
Hammacher, Solingen, Germany 
Surgical suture material Prolene EH7289H Ethicon, Somerville, NJ, USA 
Syringes BD Microfine  
(U40, 0.5 and 1 ml)  
324876 
320801 
Becton Dickinson, Heidelberg, Germany 
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Tab. 5: Therapeutic substances and solutions 
Material Product  specification Company 
   
CaelyxTM (PEGylated 
liposomal doxorubicin) 
PZN 07683692 Janssen-Cilag GmbH, Neuss, 
Germany 
 
Cisplatin local pharmacy Klinikum der Universität München, 
Apotheke Campus Großhadern, 
Munich, Germany 
Corn oil C8267 Sigma-Aldrich, Steinheim, 
Germany 
Doxorubicin local pharmacy Klinikum der Universität München, 
Apotheke Großhadern, Munich, 
Germany 
Etoposide local pharmacy Klinikum der Universität München, 
Apotheke Campus Großhadern, 
Munich, Germany 
LipoplatinTM (Liposomal 
Cisplatin) 
Provided by Regulon Inc. Regulon Inc., Athens, Greece 
Liposomal Etoposide CM-EL-02L-Alpha-
Phosphatidylcholine  
76.5 mM   
Cholesterol 56.1 mM  
1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-
N-[methoxy(polyethylene 
glycol)-750] 6.99 mM  
Etoposide 8.49 mM  
0.01 M Phosphate 
buffered Saline; 0.138 M 
NaCl, 0.0027 M KCL  
(pH 7.4) 
Encapsula NanoSciences, TN, 
USA 
Mitotane 25925-1GF Sigma-Aldrich, Steinheim, 
Germany 
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Tab. 6: Reagents and equipment for molecular analysis 
 
Material Product specification Company 
   
Fast-Real-Time PCR System 
7500 
4351105 Applied Biosystems, CA, USA 
MiRNeasy mini kit 217004 Quiagen, CA, USA 
NanoDrop 
spectrophotometer 
2000 ThermoFisher Scientific, MA, USA 
Proflex Base PCR System 4484076 ThermoFisher Scientific, MA, USA 
Spike-in control miR  
cel-miR-39 
2594091 Quiagen, CA, USA 
TaqMan Fast Universal PCR 
Master Mix 
4304437 Applied Biosystems, CA, USA 
TaqMan microRNA reverse 
transcription kit 
4366596 Applied Biosystems, CA, USA,  
TaqMan miRNA assays Hsa-miR-210 
(#000512),  
Hsa-miR-483-5p 
(#002338), 
RNU44 
(#001094),  
cel-mir-39 
(#000200) 
Applied Biosystems, CA, USA 
Total Exosome Isolation Kit 4484450 ThermoFisher Scientific, MA, USA 
Total Exosome RNA and 
Protein Isolation Kit 
4478545 ThermoFisher Scientific, MA, USA 
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Tab. 7: Solutions and their preparation protocols 
 
Solution Ingredients  
   
0.3% hydrogen peroxide in methanol hydrogen peroxide 30% 500 µl 
methanol 50 ml 
 
4% paraformaldehyde (PFA) paraformaldehyde 20 g 
 distilled water 450 ml 
10X PBS 50 ml 
 1M NaOH  
 1M HCl  
goat serum 5 µl 
   
Preparation protocol: 450 ml of distilled water are placed in a glass beaker and heated to 60°C. 
While the mixture is stirring, 20 g of paraformaldehyde powder are added to the hot water, the 
glass is covered and maintained at 60°C. Thereafter, five drops of NaOH are added and the 
solution clears within minutes. The solution must not be heated above 70°C. After receiving a 
clear solution, the glass baker is removed from heat and 50 ml of 10X PBS are added. The pH 
should be adjusted to a pH of 7.2 and the solution filled up to a final volume of 500 ml. Finally, 
the solution is filtered, placed on ice and protected from light. 
 
Acid ethanol 
 
50 ml 70% EtOH 
0.125 ml concentrated HCl 
 
Sodium citrate buffer 
 
0.1M citric acid solution 
 
21 g / 1000 ml (A) 
 0.1M sodium citrate  29 g / 1000 ml (B) 
 buffer solution: 9 ml solution A + 41 ml solution B 
 
Tap water substitute 
 
1 g NaHCO3 
10 g MgSO4*7H2O 
fill with distilled water up to 500 ml 
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Tab. 8: Software 
Software Specification 
  
Microsoft Excel 2010 Microsoft Corporation 2010, NM, USA 
Microsoft Office PowerPoint 2010 Microsoft Corporation 2010, NM, USA 
SPSS statistics 23 Ehningen, Germany 
Prism Software 3.02 Houston, TX, USA 
ImageJ 1,5b National Institute of Health (NIH), MD, USA 
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2.2 Cell culture and tumor cell preparation for tumor induction 
SW-13 cells were obtained from ATCC and recently authenticated. Adherent cells were cultured 
at 37°C providing a 5% CO2 - 95% air atmosphere. Cells were maintained in culture for at least 
two weeks before tumor induction was performed.  
 
DMEM/F-12 cell culture medium was used which was supplemented with penicillin/streptomycin 
(1%) and heat inactivated fetal bovine serum (10%, see Tab. 3). Cells were split every 3-4 days 
in a ratio of 1:8 – 1:10. Cell culture flasks were used in 75 cm² or 225 cm² size.   
 
For xenograft induction, tumor cells were subcutaneously injected into the neck of individual 
animals. For this purpose, tumor cells were grown in 225 cm² flasks for cell culture. At the day of 
tumor cell injection, four 225 cm² cell flasks were processed at the same time. After washing with 
PBS, 5 ml trypsin was added to every flask and kept at 37°C to achieve complete separation of 
tumor cells. The trypsin reaction was terminated by the addition of 18 ml cell culture medium and 
cell suspension was filled in two 50 ml falcon tubes. After a centrifugation step for 5 minutes, all 
cell pellets were dissolved in 15 ml PBS. The whole procedure was repeated with four additional 
225 cm² cell flasks to receive a total volume of 30 ml cell suspension. The suspension was 
carefully mixed and cells were counted using a Neubauer counting chamber (see Tab. 3).  
 
For the counting procedure, 1 ml of cell suspension was placed into a new falcon and mixed with 
9 ml PBS (dilution 1:10). 10 µl of this diluted cell suspension were then mixed with trypan blue 
solution (1:4) and the number of viable cells was determined using the microscope. Afterwards, 
the cell number per ml and total cell number were calculated. After the determination of the 
exact volume which contained the desired cell number for tumor cell injection, the cell 
suspension was diluted to a final injection volume of 200 µl, drawn into 1 ml syringes and 
immediately injected into the neck of the individual mice (see 2.3.2). 
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2.3 Animal experiments 
2.3.1 Housing conditions 
All animal studies were approved by the Regierung von Oberbayern and in accordance with 
regulations of the German guidelines for animal experiments. NMRI nu/nu mice (female athymic, 
6–8 weeks old) were obtained from Harlan Winkelmann GmbH and kept under pathogen-free 
conditions at an ambient temperature of 22 ± 2°C on a 12 hour light-dark cycle. Access to 
standard diet and drinking water was granted ad libitum. Handling of the animals was performed 
under a sterile airflow chamber using protection clothes, gloves and a surgical mask. The mice 
were kept in the animal house at least one week before starting the experiments.  
 
2.3.2 Preclinical tumor models and tumor induction  
Preclinical tumor models were based on subcutaneous tumor cell injection or implantation. Two 
different xenograft models for ACC (SW-13 and SJ-ACC3) were implemented in this study. Their 
characteristics are illustrated compared to the classical NCI-H295 tumor model in Fig. 8.  
Fig. 8: Overview and characteristics of SW-13, SJ-ACC3 and classical NCI-H295 xenograft tumor models 
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2.3.2.1 Cell-line based SW-13 tumor model 
Tumor induction for SW-13 and NCI-H295 xenografts was performed by a subcutaneous 
injection of tumor cells into the neck of individual mice. To achieve an accurate and reproducible 
tumor cell injection, isoflurane anesthesia was applied (6 l/min flow-rate and 5% isoflurane 
concentration). Tumor cells were prepared according to 2.2. For SW13-xenografts, 13×106 and 
11x106 tumor cells per mouse were injected in short-term and long-term experiments, 
respectively.  
 
2.3.2.2 Xenograft based SJ-ACC3 tumor model 
For SJ-ACC3 xenografts [38], cryopreserved tumor specimens of 2 mm³ size were 
subcutaneously implanted. Tumor pieces were transferred prior implantation from liquid nitrogen 
to a 37°C water bath and rinsed several times in medium 199 supplemented with 1% 
penicillin/streptomycin. Afterwards, tumor tissue was kept in medium 199 until implantation.  
 
For the implantation procedure, animals received pre- and postsurgical analgesia and were 
anesthetized according to Table 9.  
 
Tab. 9: Doses and application routes regarding anesthesia and analgesia for tumor implantation 
Drug Novalgin Domitor Ketavet Antisedan 
     
Injection s.c. i.p. i.p. i.m. 
Dosage (mg/kg mouse) 200 0.3 60 1.5 
Concentration drug (mg/ml) 500 1 100 5 
     
Dilution (0.9% NaCl) 1:10 1:10 1:20 1:10 
Injected diluted substance  
in µl per g mouse 
4 3 12 3 
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Novalgin was administered in a 12 hour rhythm post-surgery to achieve a sustained analgesia. 
Using surgical scissors and forceps, a 3-4 mm cut was induced into the neck of individual 
animals and the skin was carefully lifted to have access to a subcutaneous cavity where the 
tumor piece was placed. For tumor pieces an individual forceps was used. Afterwards, the cut 
was surgically sutured and anesthesia was antagonized with antisedan. Animals were put for the 
wake-up procedure in individual cages and warmed with infrared light. 
 
2.3.3 Therapeutic experiments  
Therapeutic experiments were performed in two different settings with short-term and long-term 
duration. For SW-13, short-term experiments were started at day 14 (n=7-8 mice) and long-term 
experiments at day 4 (n=14 mice) after tumor cell injection. For SJ-ACC3, short-term and long-
term therapeutic treatment was started after several weeks (n=4-6 mice). Only mice bearing 
successfully engrafted tumors were included in subsequent therapeutic experiments. 
 
2.3.3.1 Preparation of therapeutic drugs 
For therapeutic experiments, a preclinically adapted scheme of the classical EDP-M (Berruti) 
protocol [9, 52] was administered as already implemented in a recent study [28] (Fig. 11). The 
administration of all therapeutic treatments was performed in 24 hour intervals.  
 
Mitotane powder was stored in the refrigerator at 4-6°C until use and protected from light. Corn 
oil was autoclaved in small aliquots and used for dissolving mitotane powder at room 
temperature. After the autoclaving procedure, only clear corn oil was used. 500 mg mitotane 
powder were dissolved in 10 ml corn oil to achieve a final concentration of 50 mg/ml. As the 
powder was very poorly soluble, the corn oil had to be added carefully and mixed well for about 
10 minutes. Dissolved mitotane was filled into a falcon tube and protected from light. The 
appropriate volume for each animal was calculated and slowly drawn into 1 ml syringes (Tab. 4).  
 
Dissolved mitotane was intraperitoneally injected applying a daily dose of 300 mg/kg body 
weight over three consecutive days prior cytostatic treatment. Control animals were treated with 
appropriate volumes of autoclaved corn oil. If necessary, cytostatic drugs were dissolved in 
sterile 0.9% sodium chloride on the day of injection and intravenously applied in a 2 mg/kg dose 
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of cisplatin and lipoplatin™ as well as 10 mg/kg doses of doxorubicin, liposomal doxorubicin 
(caelyxTM), etoposide and liposomal etoposide according to the treatment modalities outlined for 
one therapeutic cycle (Fig. 11). For intravenous injections, animals were immobilized with a 
mouse restrainer and their tails were warmed up using infrared light to facilitate the injection 
procedure. 
 
2.3.3.2 Therapeutic treatments and sample collection  
In short-term experiments, tumor bearing mice were treated with one therapeutic cycle according 
to the treatment regime illustrated in Fig. 9 and 10, respectively. 48 hours after the last 
therapeutic intervention these studies were terminated and animals euthanized. After isoflurane 
anesthesia, animals were sacrificed and EDTA blood was collected and put on ice. Afterwards 
the tumors were excised and processed for paraffin embedding by immersion in 4% PFA 
overnight at 4°C. In case of sufficient material tumors were also snap-frozen in liquid nitrogen. 
EDTA-blood was centrifuged at 2000 G-force and 4°C to obtain plasma samples. Furthermore, 
100 µl of whole blood was collected in EDTA-microvettes to enable an analysis of leukocytes. 
Frozen tumor and plasma samples were kept at -80°C until further analysis was performed. 
Fig. 9: Therapeutic setting in the short-term study. Following one therapeutic cycle, tumor tissues of 
controls, EDP-M, LEDP-M and L(l)EDP-M were investigated using histology and immunohistochemistry. 
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In long-term therapeutic experiments individual mice received repeated treatment cycles with a 
therapy-free interval of ten days between the treatment cycles. During these studies, the animals 
were monitored every day and tumor sizes were measured every second day (as tumor length x 
width [cm2]).  
Fig. 10: Therapeutic setting for long-term experiments with monitoring of individual tumor development in 
the different therapeutic groups EDP-M, LEDP-M, L(l)EDP-M and controls. 
 
Tumor growth curves were analyzed for both tumor-models at least upon administration of two 
therapeutic cycles. While for SJ-ACC3 the long-term study was terminated afterwards, SW-13 
tumor bearing mice were treated with up to four therapeutic cycles to allow a more detailed 
investigation of overall survival and off target profiles of the different treatment modalities (see 
Fig. 10). In this setting mice were sacrificed when tumors reached a longest pre-defined tumor 
diameter of 1.5 cm or when specified side-effects effects (body weight loss or pathologically 
changed phenotype as abnormal body posture) occurred.  
 
For additional immunohistochemical and histological analysis also hearts and kidneys were 
snap-frozen and paraffin-embedded to enable a more detailed investigation as these organs 
represent the main off-target organs of cytostatic treatment with doxorubicin and cisplatin, 
respectively.  
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Fig. 11: Schem
atic illustration of the preclinical treatm
ent schem
es adapted from
 the clinical ED
P-M
 (Berruti) protocol. Treatm
ent protocols 
are illustrated for one therapeutic cycle including intraperitoneal and intravenous injections (adapted from
 [28]).  
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2.3.4 Histology and immunohistochemistry 
Tumor tissue, kidneys and hearts were after collection embedded in paraffin and subsequently 
processed and prepared for immunohistochemistry or histology. If not stated otherwise, all 
procedures were performed at room temperature.  
 
2.3.4.1 Paraffin embedding of tissues 
Tumor tissues, kidneys and hearts from sacrificed mice were immediately placed in a 4% PFA 
solution and kept overnight at 4°C on a shaker to enable an appropriate fixation of tissues. For 
each tissue, at least 10 ml PFA were used. Afterwards, tissues were immersed and dehydrated 
in 30%, 50% and 70% ethanol for two hours each. The following steps were performed in an 
automatic tissue processor (see also Tab. 2). Incubation in 96% ethanol (2 x 2 h) was followed 
by immersion in 100% ethanol (3 x 2 h). After these ethanol immersion steps tissue was further 
processed in xylene (2 x 2 h) and liquid paraffin (2 h and 7 h). Embedding in paraffin was 
performed at a paraffin temperature of 60°C using a tissue processor machine (Tab. 2). Paraffin 
blocks containing the tissue samples were stored at room temperature and were protected from 
light until further analysis. 
 
2.3.4.2 Preparation of tissue for immunohistochemistry and histology 
Paraffin embedded tissues were cut with a microtome in 4 µm sections. A paraffin bath set on 
40-45°C was used to achieve flattening of the tissue section. To promote an efficient drainage, 
slides were vertically removed from the bath and excess water was blotted using a paper tissue. 
Afterwards, sections were dried on glass slides overnight in an incubator at 37°C.  
 
For histological and immunohistochemical stainings, tissue sections were incubated in xylene (2 
x 6 min.) followed by an immersion in 100% ethanol (2 x 6 min.), 96% ethanol (2 x 6 min.) and 
70% ethanol (1 x 6 min.). Afterwards, sections were put in distilled water and were further 
processed according to the individual staining protocols. 
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2.3.4.3 Immunohistological and histological evaluation 
In general, tumors were immunohistochemically evaluated investigating six high power fields 
(HPF, 0.391 mm², 400x magnification) per tumor [28, 53] and histologically screened for 
necrosis. Kidneys and hearts were also investigated for pathological alterations. Assessment of 
cardiotoxic effects and pathological evaluation was performed in cooperation with the Institute of 
Pathology in Munich (Dr. Max Weiss). 
 
2.3.4.4 Ki67 immunohistochemistry 
For Ki67 immunohistochemistry, rehydrated sections were immersed in distilled water. 10 mM 
sodium citrate buffer was used to achieve efficient antigen retrieval. The slides were put into pre-
warmed citrate buffer, were boiled for 15 minutes in the microwave and cooled down at room 
temperature for one hour. The slides were then immersed for 10 minutes in 0.3% H2O2 in 
methanol to perform peroxidase blocking which avoids non-specific staining. After subsequent 
washing steps in PBS (2 x 5 min.) the slides were incubated in blocking buffer containing 3 % 
BSA, 5 % goat serum and 0.5 % Tween 20 for 15 minutes. Afterwards, primary Ki67 antibody 
(1:200 in blocking buffer) was applied which specifically stains proliferating cells.  
 
Following overnight incubation at 4°C, slides were three times rinsed for 5 minutes in PBS. 
Tissue was covered with secondary polyclonal antibody (1:200 in blocking buffer) at room 
temperature for 30 minutes. After immersion in PBS (3 x 5 min.), Vectastain ABC Kit was applied 
according to the manufacturer’s protocol (Table 2): 100 µl blocking solution, 1 µl reagent A and 1 
µl reagent B were combined 30 minutes before use and this solution was then applied to the 
tissue. Afterwards, washing steps in PBS (3 x 5 min.) were performed and primary antibody was 
visualized by incubating the tissue in 3,3´-diaminobenzidine (DAB) for 3 minutes. For 
counterstaining, Vector®methyl green nuclear counterstain was applied for 10 minutes at 60°C 
to enable cell number quantification of Ki67 positive and negative cells. The slides were very 
quickly dehydrated in 30 sec. 96% ethanol and this step was repeated. Finally, the tissue was 
repeatedly immersed for 30 sec. 100% ethanol and in xylene for 2 x 5 minutes. Permount 
mounting medium was applied to cover the slides which were afterwards dried for 24 hours over 
night. 
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2.3.4.5 TUNEL immunohistochemistry 
Apoptotic cells were visualized using the colorimetric DeadENDTM TUNEL System which 
measures the nuclear DNA fragmentation to detect apoptotic cells (see also Tab. 2).  
 
According to the manufacturer’s protocol, tissue sections were deparaffinized and rehydrated. 
Subsequent incubation with Proteinase K solution was performed for 10 minutes. The reaction 
mix was prepared as described in the protocol. During incubation with the reaction mix, 
biotinylated nucleotide is incorporated at the 3´-OH DNA supported by an enzyme referred as 
“Terminal Deoxynucleotidyl Transferase (Recombinant)” (for further information see Tab. 2). As 
described in the manual, the reaction was stopped after one hour and after several washing 
steps blocking of endogenous peroxidases was carried out with 0.3 % hydrogen peroxide. After 
washing steps, streptavidin horseradish peroxidase incubation was performed to bind 
horseradish peroxidase-labeled streptavidin to biotinylated nucleotides. In a last step, 
peroxidase substrate, hydrogen peroxide and diaminobenzidine were combined. Tissue samples 
were incubated in this mixture for 10 minutes to achieve a dark brown staining of apoptotic cells. 
70 µl of VectaMount AQ Mounting were applied at each tissue and the slides were covered 
using cover slips and dried for 24 hours. Immunohistological evaluation was performed using a 
bright field microscope (see Tab. 1). 
 
2.3.4.6 Hematoxylin/Eosin staining 
Histological evaluation of kidney and heart sections was performed using regressive 
hematoxylin/eosin staining. Tissue was deparaffinized by repeatedly immersing the slides for 5 
min. in xylene, followed by 3 x 3 minutes washing steps in 100% ethanol and 3 min. in 96% and 
80% ethanol. Afterwards, the slides were immersed for five minutes in distilled water. While the 
sections were immersed in the water, the surface of hematoxylin was skimmed with a wipe to 
remove oxidized particles. Excess water from the slide and slide holder was blotted before the 
slides were incubated for 2.5 minutes in hematoxylin. Tap water substitute (Tab. 7) was used to 
blue the stainings for 5 minutes. After staining with hematoxylin, the slides were ten times dipped 
into acid ethanol for de-staining and immersed for 2 x 1 min. in tap water substitute followed by 
washing steps in distilled water. Excess water was blotted from the slides before immersion into 
eosin for 45 seconds. Slides were immediately put into 95% ethanol for 2 x 5 min. and 100% 
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ethanol for 2 x 5 minutes. Excess ethanol was blotted before going into final xylene dehydration 
steps for 2 x 10 min. and afterwards the slides were covered using permount mounting medium. 
 
2.4 Molecular Analyses  
For micro-RNA (miR) analysis with quantitative real-time PCR (RT-qPCR), SW-13 and SJ-ACC3 
tumor specimens and plasma samples of the short-term experiments were processed to isolate 
the total RNA of each sample (different kits and equipment see Tab. 6).  
 
Tumor tissue was pulverized in liquid nitrogen and processed according to the instructions in the 
miRNeasy mini kit which is designed to purify total RNA including miR and other small RNA 
molecules. After the isolation procedure, 30 µl RNA in distilled water were obtained.  
 
According to the manufacturer’s total exosome isolation and total exosome RNA and protein 
isolation kit, isolation of circulating RNA from plasma exosomes was performed by processing 
the plasma samples. Exosomes are defined as small vesicles which are secreted by all types of 
cultured cells, contain nucleic acid and proteins and are released to extracellular fluids in 
exocytic bursts by fusion with the cell surface (see also in the manufacturer’s protocol, Tab. 6). 
Before Acid-Phenol Chloroform extraction, spike-in control miR cel-miR-39 was added and then 
total RNA isolation was proceeded as described in the manual’s instructions. Finally, the 
concentration of RNA was determined using NanoDrop 2000 spectrophotometer and RNA 
samples were stored at -80°C until use. If necessary, total RNA was diluted to a concentration of 
2 ng/µl and reverse transcribed using specific TaqMan MicroRNA Reverse transcription kit on 
Proflex Base PCR System.  
 
For reverse transcription, reactions were run in a total volume of 7 µl master mix, 3 µl primer and 
5 µl RNA sample as described in the manufacturer’s protocol. Quantitative RT-PCR was 
performed using a 7500 Fast-Real-Time PCR System with TaqMan Fast Universal PCR Master 
Mix (2x) and TaqMan miRNA assays. The reaction was performed in a total volume of 15 µl 
containing 6.1 µl nuclease-free water, 7.5 µl Taqman Fast Universal PCR Master Mix, 0.5 µl 
TaqMan miR assays and 0.9 µl reverse transcription product. Reactions were run in duplicates 
on a 96-well plate.  
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Human primer assays were as follows: Hsa-miR-210 (#000512) and hsa-miR-483-5p (#002338) 
(Tab. 6). For tumor samples RNU44 (#001094) and for plasma samples cel-mir-39 (#000200) 
were used as housekeeping genes [40, 54].  
 
For the evaluation of changes in miR level upon therapy with NaCl or LEDP-M in each mouse, 
the ratio of intratumoral to circulating miR level was calculated (referred to as “miR ratio”) after 
normalization to controls (% of controls) [53]: 
A value of 1 indicates unchanged levels in tumor and plasma. Accordingly, a value of >1 reveals 
an elevated expression of intratumoral miR while a ratio of <1 indicates elevated expression of 
circulating miR [53]. 
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2.5 Clinical experiments 
Six patients with very advanced ACC that have benefited in the past from EDP-M were offered 
liposomal doxorubicin or liposomal cisplatin (referred here as liposomal EDP-M, lipEDP-M) on a 
compassionate-use basis (see Tab. 1). All patients had experienced toxicity upon classical EDP-
M treatment and/or desired experimental therapy.  
 
All study participants were informed by the experimental nature of this drug administration and 
gave informed consent in verbal and written form. Following criteria were evaluated: 1. reason 
for liposomal EDP-M, 2. change in sum of target lesions, 3. best objective response, 4. serious 
side-effects, 5. kidney function (using the MDRD formula ml/min/1.73 m²) and 6. individual 
patient’s evaluation of liposomal EDP-M protocol. Patient recruitment, collection and evaluation 
of data were performed in a cooperation project, managed by Prof. Dr. med. Fassnacht-Capeller 
(Wuerzburg) and Prof. Dr. med. Felix Beuschlein (Munich). 
 
2.6 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM). For statistical analysis, Prism 
Software 3.02 (Houston, TX, USA) or SPSS statistics 23 were utilized. After analysis of normality 
distribution, One-way ANOVA (analysis of variance) followed by Bonferroni’s Multiple 
Comparison Test (comparing all treatment groups) or unpaired t-test was applied. Both tests 
included an adjustment of 95% confidence interval (CI). For analysis of survival, log-rank (Mantel 
Cox) test was utilized. Statistical significance is defined as p<0.05 and indicated as asterisk (*, 
p<0.05; **, p<0.01; ***, p<0.001) in the figures if not stated otherwise. 
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3. Results 
Tumor bearing animals were treated according to the treatment schemes for short-term or long-
term experiments (see 2.3.3.2). For short-term experiments, tumors were investigated by 
histology and immunohistochemistry. Blood samples were analyzed for leukocyte count. In long-
term experiments, tumor development and off-target profiles were assessed. 
 
3.1 Short-term therapeutic efficacy  
Anti-tumoral efficacy of EDP-M, LEDP-M and L(l)EDP-M was investigated in SW-13 and SJ-
ACC3 tumors after administration of one therapeutic cycle (see Fig. 11). Experimental setting, 
therapeutic regimens and treatment groups are described in 2.3.3. 48 hours after the last 
therapeutic intervention animals were euthanized. Blood samples were collected and SW-13 and 
SJ-ACC3 tumor tissues were investigated for tumor cell proliferation by Ki67 
immunohistochemistry. Furthermore, induction of apoptosis was analyzed by TUNEL 
immunohistochemistry and tumors were histologically evaluated utilizing hematoxylin/eosin 
staining (see 2.3.4).  
 
3.1.1 Evaluation of the total number of tumor cells 
For both xenografts models, highest total number of tumor cells (Ki67-positive and negative 
fraction [cells/high-power field/tumor]) was, as expected, detected in the control groups (SW-13: 
28.9 ± 2.2, Fig. 12A;  SJ-ACC3: 35.9 ± 1.3; Fig. 13A).  
 
While all treatments showed anti-proliferative effects against SW-13 revealing highest efficacy 
upon L(l)EDP-M administration (EDP-M: 20.5 ± 1.6, p<0.01; LEDP-M 17.2 ± 1.3 p<0.001 and 
L(l)EDP-MP-M 14.7 ± 0.9, p<0.001, versus controls; Fig. 12A), for SJ-ACC3 only EDP-M 
induced a significant reduction in the number of tumor cells compared with controls (EDP-M: 
30.3 ± 1.2, p<0.05; LEDP-M 31.5 ± 1.8, p>0.05 and L(l)EDP-MP-M 32.5 ± 0.3, p>0.05 versus 
controls; see Fig. 13A).  
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Fig. 12: Immunohistochemical analysis of SW-13 tumor tissues derived from the short-term therapeutic 
study. The quantification of the total number of tumor cells per HPF (Ki67-positive and Ki67-negative cells) 
is illustrated in (A). Representative pictures are presented for NaCl (B), EDP-M (C), LEDP-M (D) and 
L(l)EDP-M (E) treated tumors. Statistical significance versus controls is indicated with asterisks (*, p<0.05; 
**, p<0.01; ***, p<0.001). 
 
For SW-13, the detected decrease in the number of tumor cells was furthermore accompanied 
by a severe condensation of nuclei after treatment with EDP-M, LEDP-M and L(l)EDP-M (Fig. 12 
C-E) compared to controls (Fig. 12B) which was not evident in SJ-ACC3 tumors (Fig. 13 B-E). 
Fig. 13: Analysis of SJ-ACC3 tumor tissue obtained from the short-term therapeutic experiment. Using 
Ki67 immunohistochemistry and methyl green counterstaining, the total number of tumor cells (Ki67-
positive and Ki67-negative cells) was quantified (A). Representative pictures for NaCl, EDP-M, LEDP-M 
and L(l)EDP-M treated tumors are displayed in B-E, respectively. Statistical significance versus controls is 
denoted with asterisks (*, p<0.05; **, p<0.01; ***, p<0.001).  
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3.1.2 Investigation of apoptosis 
Tumor tissues of both xenografts models were furthermore investigated utilizing the TUNEL 
assay to enable a detection of apoptotic cells (protocol see 2.3.4.5). Quantification of apoptosis 
revealed for both tumor models tendencies towards induction of apoptosis upon the specific 
therapeutic treatments (SW-13: EDP-M: 3.0 ± 0.5, p=1.000; LEDP-M 4.2 ± 0.7, p=0.323 and 
L(l)EDP-M 4.3 ± 0.9, p=0.325 Fig. 14A; SJ-ACC3: EDP-M: 5.5 ± 0.8, p=0.280; LEDP-M 5.1 ± 
0.5, p=0.772 and L(l)EDP-MP-M 5.4 ± 0.4, p=0.361 versus controls; Fig. 14B), but the detected 
values did not reach statistical significance for any treatment in comparison to controls (SW-13: 
2.4 ± 0.5; SJ-ACC3: 3.5 ± 0.8; Fig. 14A and 14B, respectively).  
Fig. 14: Quantification of TUNEL positive cells in tumor tissue of SW-13 (A) and SJ-ACC3 (B) xenografts. 
Statistical analysis revealed overall no significant differences in both xenograft models. 
 
3.1.3 Histological evaluation of necrosis in tumor tissues 
Histological analysis was performed using regressive hematoxylin/eosin staining. For SW-13, 
the anti-tumoral effects shown for Ki67 immunohistochemistry (see 3.1.1) were thereby 
histologically confirmed by a semi-quantitative analysis of necrosis using hematoxylin/eosin 
staining. Each SW-13 tumor was histologically analyzed and categorized regarding necrotic 
areas (from low to high levels of necrosis with 0 to 3, respectively) as illustrated in Fig. 15M. 
Representative pictures for these semiquantitative categories are shown in Fig. 15I-L. While 
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necrosis was rarely detected for the control group, the presence and grades of necrosis 
increased upon EDP-M over LEDP-M to L(l)-EDP-M administration on SW-13 xenografts as 
shown in Fig. 15A-D. Such effects were not evident for SJ-ACC3 tumors (Fig. 15E-H). 
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3.2 Long-term therapeutic efficacy 
In subsequent long-term experiments, anti-tumoral effects of the different therapeutic treatments 
were investigated on SW-13 and SJ-ACC3 tumor bearing mice. Therapeutic regimens and 
treatment groups were unaltered compared to short-term experiments (see 2.3.3).  
 
In contrast to short-term evaluation, primary endpoint of these long-term studies was the tumor 
development (expressed as length x width in cm²) upon repeated treatment with EDP-M, LEDP-
M or L(l)EDP-M (Fig. 16). Between each cycle a therapy free interval of ten days was set.  
Fig. 16: Antitumoral effects of the different treatment protocols on SW-13 xenografts after two therapeutic 
cycles measured as tumor length x width [cm²]. Significant differences compared to controls are illustrated 
with: *, p<0.05; **, p<0.01; ***, p<0.001. 
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The long-term experiment confirmed the previously obtained results from the SW-13 short-term 
study and demonstrated anti-tumoral effects for all treatment modalities. Moreover, highest 
tumor size reduction upon two therapeutic cycles was detected upon L(l)EDP-M treatment 
compared to controls (cm², day 29 after tumor cell injection, NaCl: 1.02 ± 0.08; EDP-M: 0.57 ± 
0.10, p<0.01; LEDP-M 0.62 ± 0.11, p<0.05; L(l)EDP-M: 0.48 ± 0.07, p<0.001, Fig. 16). 
 
In contrast, for SJ-ACC3 no significant differences regarding the tumor development were 
detectable upon two cycles with the different therapeutic regimens (day 56 post implantation of 
tumor xenografts, NaCl: 0.30±0.14; EDP-M: 0.14±0.06, p>0.05; LEDP-M 0.12±0.03, p>0.05; 
L(l)EDP-M: 0.17±0.08, p>0.05; Fig. 17). 
Fig. 17: Effects on the SJ-ACC3 tumor xenograft size [cm²] after treatment with two therapeutic cycles of 
the different treatment regimens EDP-M, LEDP-M, L(l)EDP-M and controls. 
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3.3 Tolerability and off-target profiles  
To assess the acute tolerability of the different treatment regimens, typical off-target organs of 
the classical EDP-M regimen were investigated. Moreover, blood samples were analyzed 
regarding leukocyte count as leukopenia is known to be a well recognized and common dose-
limiting side effect of the classical clinical gold standard.  
 
Furthermore, long-term tolerability and overall survival of the different treatment modalities were 
investigated for up to four treatment cycles. 
 
3.4 Analysis of leukocytes upon short-term treatment 
Leukocytes count was performed for both xenografts models after one therapeutic treatment 
cycle and is shown in Fig. 18. The analysis not only confirmed for the classical EDP-M regimen 
a significant reduced number of leukocytes (3.41 ± 1.37), it also revealed such an effect for the 
liposomal treatment arms LEDP-M (3.81 ± 1.14) and L(l)EDP-M (3.81 ± 1.30) compared to 
controls (7.19 ± 2.26, p<0.001). 
Fig. 18: Analysis of leukocyte count after one therapeutic treatment cycle with EDP-M, LEDP-M, L(l)EDP-
M and controls in SW-13 and SJ-ACC3 tumor bearing mice. Stars denote significant differences 
compared with L(l)EDP-M (*, p<0.05; **, p<0.01; ***, p<0.001). 
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3.5 Analysis of survival and lethal side-effects upon long-term treatment 
In an attempt to investigate the long-term tolerability of the different treatment modalities, 
therapeutic treatment of SW-13 tumor bearing mice (as already outlined for two cycles in 3.2) 
was continued for up to four cycles.  
Fig. 19: Overall survival (A) and appearance of pre-defined endpoints leading to study determination (B) 
in the SW-13 long-term study. Treatment of tumor-bearing mice was continued for up to four therapeutic 
cycles with either NaCl, EDP-M, LEDP-M or L(l)EDP-M. P-values are illustrated for NaCl, EDP-M and 
LEDP-M compared to L(l)EDP-M  treatment (Mantel-Cox (log-rank) analysis). 
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Following this approach, overall survival was monitored with endpoints such as 1.5 cm longest 
tumor diameter and appearance of severe adverse effects (such as body weight loss or 
abnormal body posture) for study determination.  
 
According to these criteria, L(l)EDP-M treatment led to significantly prolonged overall survival not 
only in comparison to controls (p<0.0001), but also compared to EDP-M (p=0.003) as shown in 
Fig. 19A. As illustrated in figure 19B, all control animals had to be euthanized due to the longest 
tumor diameter of 1.5 cm which occurred also in 43% of EDP-M, 50% of LEDP-M and 29% of 
L(l)EDP-M treated animals. In contrast, treatment with EDP-M led to a pronounced development 
of side effects (including weight loss and abnormal body posture) in 6 of 14 (43%) cases while 
LEDP-M (0 of 14, 0%) and L(l)EDP-M (1 of 14, 7%) treatments reduced such incidents (Fig. 
19B). 
 
3.6 Analysis of hearts and kidneys  
Investigation of kidneys and hearts was also performed after up to four treatment cycles in SW-
13 tumor bearing mice as these organs are known to be targeted by classical formulations of 
cisplatin and doxorubicin. 
 
While HE stainings of kidneys from control mice (n=14) did not reveal any pathological finding, 5 
of 14 kidneys in the EDP-M group displayed severe pathologic alterations by occurrence of 
tubular casts (Fig. 20). Such histological changes were not detectable in the therapeutic arms 
including liposomal formulations of cisplatin. Specifically, in none of 14 animals treated with 
LEDP-M and only one of 14 mice treated with L(l)EDP-M minor structural renal alternations were 
found.  
 
Moreover, also mild cardiotoxic effects were detectable in the EDP-M arm exclusively. While in 
two of five investigated hearts of the EDP-M group vacuole formation and single cell necrosis 
could be detected (see Fig. 21), such effects were not apparent in the liposomal treatment 
groups.  
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Fig. 20: Pathological exam
ination of H
E stained kidneys from
 controls (N
aC
l) (A, E), ED
P
-M
 (B, F), LED
P
-M
 (C
, G
), L(l)E
D
P
-M
 (D
, H
) in 
100x (A
-D
) and 400x (E
-H
) m
agnification, respectively. ED
P
-M
 treatm
ent led to distinct pathological alteration in kidney tissue, as illustrated 
in 25x (I) and 50x (J) m
agnification. Such severe alterations w
ere absent after treatm
ent w
ith LED
P
-M
 and L(l)ED
P
-M
 regim
ens. 
56 
 57 
Fig. 21: Pathological examination of H&E stained hearts (400x magnification) upon long-term treatment 
with control (NaCl, A), EDP-M (B), LEDP-M (C) and L(l)EDP-M (D). Black arrows point at vacuole 
formation and single cell necrosis which occurred exclusively in hearts of mice treated with classical EDP-
M regime. 
 
3.7 Circulating miR-210 as potential biomarker for therapeutic efficacy 
Based on a pilot experiment analyzing a panel of various miRs (miR-195, miR-210, miR-483-3p, 
miR-483-5p and miR-503) on NaCl, EDP-M and LEDP-M treated NCI-H295R xenografts (data 
not shown) and data from the literature, two miRs were selected for examination as putative 
therapeutic biomarkers: miR-483-5p and miR-210. To investigate such a role for the pre-
selected miRs, the ratio of intratumoral to circulating miR (miR ratio) was calculated for each 
individual animal (see chapter 2.4).  
 
After one therapeutic cycle with NaCl or LEDP-M, miR ratio revealed no treatment-dependent 
changes for miR-483-5p expression in both tumor models (SW-13: control 1.38 ± 0.52, LEDP-M 
0.81 ± 0.11, SJ-ACC3: control 1.02 ± 0.12, LEDP-M 1.74 ± 0.43; Fig. 22A). In contrast, miR-210 
ratio was significantly altered in SW-13 after LEDP-M treatment (0.32 ± 0.06) compared to 
controls (1.20 ± 0.31) indicating elevated circulating miR-210 levels. Such an effect was not 
evident for SJ-ACC3 (control 1.26 ± 0.74, LEDP-M 0.83 ± 0.32; Fig. 22B).  
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Fig. 22: Quantitative Real-Time PCR was performed to analyze intratumoral and circulating microRNA 
483-5p (A) and microRNA-210 (B) of control (NaCl) and LEDP-M treated SW-13 and SJ-ACC3 tumor 
bearing mice. For an evaluation of changes upon antitumoral therapy in each animal, the ratio of 
intratumoral to circulating miR level was calculated after normalization to controls. A value of 1 suggests 
equal levels in tumor and plasma sample. A value of >1 indicates an elevated expression of intratumoral 
microRNA while a ratio of <1 reveals an elevated expression of circulating microRNA. Significant 
differences are denoted with *, p<0.05. 
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3.8 Clinical data 
Clinical data were obtained within a cooperation project of the university hospitals Wuerzburg 
and Munich, managed by Prof. Dr. med. Martin Fassnacht-Capeller and Prof. Dr. med. Felix 
Beuschlein, respectively. For this pilot project, six patients were selected and received a 
liposomally modified EDP-M scheme (lipEDP-M) including at least one liposomal drug on a 
compassionate use basis.  
 
In general, the drug regimens were well tolerated. However, none of these heavily pre-treated 
patients experienced an objective tumor response. Kidney function was clearly impaired in three 
patients due to earlier EDP-M related renal toxicity. Remarkably, the glomerular filtration rate 
(measured by MDRD formula) did not further deteriorate during antitumoral therapy with 
liposomal drug regimens. However, one patient experienced acute kidney failure after receiving 
the second cycle of lipEDP-M which was most likely due to sepsis. Of particular importance, 
three of six patients evaluated the liposomally modified regimen better tolerable than the 
previously administered conventional EDP-M scheme. Two patients mentioned no difference 
and one study participant experienced no subjective toxicity following EDP-M or lipEDP-M 
treatment. 
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4. Discussion  
Clinical translation of novel therapeutic regimens for adrenocortical carcinoma (ACC) remains 
challenging, particularly due to observed tumor heterogeneity regarding tumor growth rate, 
treatment response and overall survival. Furthermore, ACC exhibit different subtypes as for 
example adult vs. pediatric and hormonally active vs. hormonal inactive tumors. Combination 
chemotherapy including etoposide, doxorubicin and cisplatin together with mitotane (EDP-M) 
represents the current systemic standard protocol for advanced ACC, which are not amenable 
for surgery [9]. Despite surgical and therapeutic intervention, ACC are conflicted by a very poor 
prognosis and unfavorable long-term survival outcome [3]. Classical therapeutic treatment with 
multi-chemotherapeutic regimens as EDP-M induces severe and dose-limiting adverse effects 
[1, 9, 10]. Moreover, high variability in therapeutic responsiveness [55] makes it almost 
impossible for physicians to weigh patients’ long-term benefit and life quality against highly toxic 
combination chemotherapy protocols. Therefore, the most pivotal tasks to be accomplished are 
the development of more effective, but also more tolerable therapeutic regimens. Another 
important aim is the establishment of reliable therapeutic biomarkers which help to distinguish 
reasonable therapeutic consequences for ACC patients [56].   
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4.1 Therapeutic efficacy of liposomal EDP-M regimens 
In the present study, antitumoral efficacies of the classical EDP-M regimen as well as of two 
novel liposomal protocols (LEDP-M and L(l)EDP-M) were evaluated after short-term and long-
term treatment in two different tumor xenograft models for ACC (SW-13 and SJ-ACC3).  
For SW-13, both classical and liposomal treatment regimens led to antitumoral effects after one 
therapeutic cycle revealing the highest efficacy in the liposomal arms regarding tumor cell 
proliferation and induction of necrosis. In particular, L(l)EDP-M led to a highly significant 
reduction in tumor cell count, accompanied by a distinct induction of necrosis following one 
therapeutic cycle. Subsequent long-term experiments confirmed these findings and 
demonstrated a significant reduction of tumor size in all treatment arms accompanied by 
improved overall survival with LEDP-M and L(l)EDP-M treatment.  
In general, a higher antitumoral efficacy of liposomal regimens can be explained by the 
occurrence of passive tumor targeting and prolonged plasma stability as reported for liposomal 
carriers [14, 22]. Moreover, the observed antitumoral efficacy of both liposomal regimens is in 
accordance with existing preclinical data for ACC. Hantel et al. demonstrated that the tumor cell 
lines NCI-H295 and SW-13 are characterized by an extraordinary uptake phenomenon of 
liposomes which supports the application of liposomal drugs for this tumor entity [27]. 
Accordingly, a recent in vivo study using NCI-H295 xenografts demonstrated that LEDP-M 
treatment led to a significant reduction of tumor sizes compared with the classical scheme 
composed of EDP-M [28]. Thus, the present study utilizing SW-13 xenografts supports the 
previous experiments on NCI-H295R xenografts [28] and predicts superior therapeutic efficacies 
of liposomal treatments chemotherapies for adult ACC. Liposomal chemotherapies have 
successfully been applied in clinical practice for a wide range of tumor entities [17, 57-59] and 
therefore represent a therapeutic tool which could be rapidly transferred into clinical use. 
In contrast to the effects obtained for NCI-H295R and SW-13, liposomal treatment regimens 
were not effective against SJ-ACC3, a tumor model of pediatric origin. For this xenograft model 
slight therapeutic responsiveness was observed upon one therapeutic cycle with classical EDP-
M, exclusively. Regarding long-term efficacy, none of the investigated treatment schemes 
induced a significant therapeutic response.  
 
These findings are consistent with the fact that pediatric ACC patients demonstrate even with 
surgical and chemotherapeutic intervention a very poor prognosis and low tumor response [60]. 
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ACC occurring in early childhood represent a distinct entity compared to adult ACCs with 
regards to their origin, clinical manifestation, molecular profiles and prognosis [61]. Together with 
their low prevalence, this aggravates the situation to find effective treatment options for these 
tumors [61, 62]. Also, acute and long-term complications of highly toxic regimes as EDP-M are 
of crucial importance in the therapy of children and deserve special attention as current medical 
treatment options lead to irreversible off-target effects and impairments [9, 60].  
 
In both pediatric and adult ACC, the most commonly used combination for ACC treatment is 
EDP in combination with mitotane [9, 10, 60, 63]. In adult patients, mitotane is the only approved 
drug for ACC treatment but for pediatric ACC the use of mitotane has not been evaluated 
systematically [64]. Only recently, a preclinical study of Pinto et al. [38] demonstrated that single-
agent therapy with cisplatin, but not with etoposide and doxorubicin, induced potent anti-tumoral 
effects. In addition, the study identified topotecan as a potentially effective agent for the 
treatment of pediatric ACC. Liposomal cisplatin (lipoplatinTM) is already under clinical 
investigation (phase I, II and III trials) and also liposomal topotecan is preclinically evaluated for 
other tumor entities [13, 23-25, 57, 65, 66]. Accordingly, a combinatorial approach of liposomal 
formulations of cisplatin and topotecan could represent an interesting strategy to improve 
therapeutic benefit and tolerability for pediatric ACC patients in the future. 
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4.2 Off-target profiles of liposomal EDP-M regimens in preclinical tumor xenografts 
Regarding the clinical application of EDP-M protocols, not only therapeutic benefit but also 
tolerability including acute and long-term complications have main impact on clinical applicability 
[1, 56]. The combination chemotherapy protocol including the cytotoxic drugs etoposide, 
doxorubicin and cisplatin induces highly toxic off-target effects characterized by dose-limiting 
hematological toxicities, gastrointestinal impairment and other toxicities as irreversible 
cardiotoxic and nephrotoxic events [9, 10].  
As one example, dose-limiting leucopenia is a known and common complication [9]. Unfavorably 
and confirming the results of Hantel et al. 2014 [28], leukocyte counts were reduced not only 
after treatment with EDP-M and LEDP-M, but also in the L(l)EDP-M regimen in this recent study. 
Interestingly, even though other in vivo studies demonstrated for liposomal etoposide higher 
maximal tolerable doses, the same experiments revealed still an induction of myelosuppression 
[67, 68]. Thus, overall an improvement of clinically observed leucopenia is not to be expected in 
the administration of liposomal EDP-M regimens.  
In addition, also nephrotoxicity and cardiotoxicity impede the application of EDP-M in clinics. 
Nephrotoxicity is the main dose-limiting side effect of cisplatin therapy. The most serious and 
common presentation is acute kidney injury which occurs in 20-30% of cisplatin-treated patients 
[69]. Also, following doxorubicin treatment, approximately one out of four patients experiences 
congestive heart failure after exceeding cumulative doses of 500 mg/m² [11, 70]. More recent 
data furthermore indicate development of cardiomyopathy after anthracycline-based 
chemotherapy not only at much lower cumulative doses but even after 4 to 20 years in almost 
25% of patients [12, 71]. These findings are of decisive importance not only for adult patients, 
but also especially for children, given that cytotoxic effects of anthracyclines are generally 
thought to be irreversible [11]. Such impairments have been studied and described extensively 
in the literature and are known to be common adverse effects of doxorubicin and cisplatin, 
respectively [11, 57, 69, 72, 73].  
In the present study, kidneys and hearts were histologically assessed following multiple 
treatment cycles with EDP-M. Histological evaluation confirmed pathological alterations upon 
EDP-M therapy in kidneys and hearts compared to controls revealing massive tubular casts and 
a development of myocyte necrosis and vacuole formation, respectively. LEDP-M and L(l)EDP-
M protocols were very likely to improve off-target profiles as liposomal doxorubicin and liposomal 
cisplatin have both been extensively studied in this context [17, 25, 57, 74-76]. In recent years, 
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several clinical studies have provided evidence for a highly significant reduction of cardiotoxicity 
[14, 74] and nephrotoxicity [13, 57, 76] using liposomal formulations of doxorubicin and cisplatin 
instead of their parental drugs.  
In the current study, the analysis of kidneys and hearts upon liposomal treatment clearly 
confirmed an improvement of such off-target profiles in comparison to classical EDP-M 
treatment. Even after up to four treatment cycles no comparable cardiotoxic and nephrotoxic 
impairment was detectable upon treatment with LEDP-M or L(l)EDP-M.  
In addition, overall survival upon multiple treatment cycles was analyzed including not only a 
monitoring of the longest tumor diameter, but also a surveillance of adverse effects using pre-
defined criteria for study determination. While a high number of EDP-M treated animals 
developed side-effects as body weight loss and abnormal body posture, comparable effects 
were not apparent upon treatment with liposomal regimens. Therefore, the present study 
furthermore demonstrates significantly increased tolerability of L(l)EDP-M treatment compared to 
EDP-M regimen.  
  
 66 
4.3 MiR-483-5p and miR-210 as therapeutic biomarkers for ACC 
Despite an improvement of therapeutic efficacy and off-target profiles, quality of life during and 
after therapeutic treatment with highly toxic regimen is of pivotal interest for patients in clinical 
practice. ACC are characterized by high heterogeneity mostly with highly malignant and 
progressive potential. However, in rare cases ACC can also reveal a more indolent and less 
aggressive phenotype [9, 10]. Accordingly, the therapeutic responsiveness upon EDP-M can 
range from high to completely ineffective. Rarely observed long-term cures combined with 
irreversible side-effects of EDP-M treatment furthermore worsen the situation for physicians and 
treated ACC patients. As appropriate markers for therapeutic efficacy do not exist [56], the 
assessment and weighing of multiple EDP-M treatment cycles against long-term benefit and 
quality of life remains an almost untraceable task in clinical practice. 
 
In recent years, increased attention has been drawn to the analysis and quantification of micro-
RNA (miR). MiR are defined as small non-coding RNA molecules and are influencing the gene 
expression, thereby representing important regulators for physiological and pathological 
conditions as well as tumorigenesis [40, 43]. For a variety of tumor entities including ACC, 
specific signatures of aberrant miR expression patterns have been demonstrated [40, 43]. 
Progression of cancer, therapeutic response and survival rates have been correlated with levels 
of circulating miRs in several studies. Such investigations of blood samples indicate the potential 
of miR to monitor therapeutic responses applying minimal invasive techniques [8, 40].  
 
In this research project, miR-483-5p and miR-210 levels in tumors and plasma exosomes were 
investigated as potentially interesting therapeutic biomarkers for ACC. The MIR483 gene is 
located in the second intron of the IGF2 gene and high miR-483-5p was found to be paralleled 
by high expression of IGF2 and to correlate with malignancy in ACC [43, 45]. For miR-210, also 
known as hypoxia-inducible miR-210 or “micromanager of the hypoxia pathway” [50], an 
involvement in cell cycle regulation, mitochondrial metabolism, DNA repair mechanisms and 
angiogenesis has been reported [50, 51]. Regarding ACC, high miR-210 levels have been 
correlated with parameters of tumor aggressiveness as well as clinical outcome [44]. Similar 
findings have been reported for a variety of other tumor entities in clinical studies [46-48, 77]. 
 
SW-13 and SJ-ACC3 tumor tissue and plasma exosomes were analyzed after one therapeutic 
cycle with control (NaCl) or LEDP-M treatment, as LEDP-M had revealed anti-tumoral efficacy in 
SW-13 but not in SJ-ACC3. For each animal, the ratio of intratumoral to circulating miR was 
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calculated to detect individual treatment-dependent changes in tumor and circulating miR. In this 
setting, investigation of miR-483-5p revealed no treatment-related changes. However, for SW-13 
significantly altered miR-210 ratio could be detected, which resulted from elevated circulating 
miR-210 levels following LEDP-M treatment.  
 
This finding is in accordance with a clinical study investigating miR-210 level following 
neoadjuvant therapy in breast cancer patients. In this present study, increased miR-210 levels 
after therapy could be detected. However, in this study this finding could not be correlated with a 
long-term outcome so far [78]. Thus, as SW-13, but not SJ-ACC3, responded to LEDP-M 
therapy and significant alterations in circulating mir-210 ratio were detected exclusively for SW-
13 upon treatment, miR-210 could represent a potentially interesting therapeutic biomarker for 
ACC.  
 
However, additional investigations are required to further clarify the underlying mechanisms of 
altered circulating miR levels. One important factor could be the influence of the individual 
therapy (as classical or liposomal chemotherapy) on miR levels [43]. Liposomes might interfere 
with the formation of exosomes which could affect the analysis and the following results. 
Furthermore, a correlation of therapeutic response and changes in miR ratio needs to be studied 
at different time points following therapeutic intervention as time-dependent fluctuations in miR 
level upon therapy are not clarified yet in detail [79]. Studies which investigated miR levels after 
different therapeutic interventions include a monitoring of miR levels from two weeks up to six 
months post treatment [79-81]. In the present study, animals were sacrificed 48 hours after the 
final treatment and therefore this recent miR analysis includes only one time point. Additional 
investigations considering these factors would be of high importance in order to establish miR-
210 as a therapeutic biomarker. Such a biomarker would be helpful assessing treatment efficacy 
and thereby improving the situation for ACC patients.   
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4.4 Liposomally modified EDP-M in clinics 
Approaches to the development of novel therapeutic biomarkers for ACC treatment should be 
seen in the context of long-term projects for the future. This perception stands in contrast to the 
administration of liposomal doxorubicin and cisplatin for ACC patients as such formulations are 
already administered for a variety of other malignancies [14, 19, 22, 57]. As caelyxTM and 
lipoplatinTM are already in clinical use for other tumor entities [13, 22], efficient transfer of LEDP-
M into clinical practice would be possible and could be rapidly achieved.  
After promising results of the described preclinical experiments and in view of potential benefits 
for patients, liposomally modified EDP-M protocols were investigated in six patients revealing 
advanced ACC tumors. This pilot project of the two ACC centers in Wuerzburg and Munich was 
supervised by Prof. Dr. med. Martin Fassnacht-Capeller and Prof. Dr. med. Felix Beuschlein, 
respectively. The investigation of this small patient cohort treated with liposomally modified EDP-
M regimen demonstrated for the first time that liposomal chemotherapies in ACC patients were 
overall well tolerated. Even though antitumoral effects could not be observed in these patients, it 
should be taken into consideration that all enrolled patients were heavily pre-treated including 
standard EDP-M and other cytotoxic drugs. Consequently, the observation that none of the 
patients experienced an objective tumor response has to be seen in the context of very 
advanced disease [82] and pre-treatment with standard EDP-M, which makes induction of drug 
resistance more likely [83]. Therefore, this setting might not represent the optimal time point for a 
therapeutic intervention with liposomal preparations.  
 
In conclusion, an implementation of liposomal cisplatin (lipoplatinTM) and doxorubicin (caelyxTM, 
myocetTM) would allow a swift clinical translation, could increase therapeutic efficacy, but mainly 
improve tolerability and thereby quality of life for ACC patients with advanced disease. 
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4.5 Perspectives and outlook 
High antitumoral efficacy of liposomal preparations and high dose-limiting toxicity of existing 
multi-chemotherapeutic regimen have led to the idea to adapt and re-establish clinical treatment 
schemes for ACC. The fact that recent preliminary data demonstrate successful application of 
liposomal drugs in ACC patients might represent the starting point to reconsider, modify and 
change existing treatment protocols of ACC in general.  
Liposomally modified EDP-M protocols including liposomal formulations of cisplatin (lipoplatinTM) 
and/or doxorubicin (myocetTM, caelyxTM) hold great potential to improve the current medical 
situation in the treatment of ACC. Furthermore, the promising results of this preclinical study 
including the first successful application of liposomally modified EDP-M in patients recently 
initiated an EMA (European Medical Agency) orphan drug status application for lipoplatinTM in 
ACC treatment. Accordingly, most recent plans for a design of novel clinical trials include 
lipoplatinTM in a larger patient cohort. The idea to use single agent cisplatin therapy with or 
without mitotane transpired already years ago, but was mainly limited by occurring toxicities [84, 
85]. Due to its improved tolerability, lipoplatinTM could be used in higher doses as conventional 
cisplatin and could also be combined with low-radiation therapy or mitotane in adjuvant 
therapeutic settings after radical resection or advanced disease patients [84, 86].  
Thus, the described findings demonstrate the potential to have a great impact on clinical ACC 
treatments and could thereby improve therapeutic outcome and life quality of ACC patients in 
the near future. 
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5. Summary 
Adrenocortical carcinoma (ACC) is a rare but highly heterogeneous malignancy. Severe dose-
limiting adverse effects and heterogeneous tumor response strictly limit systemic therapy of 
ACC. Most recent preclinical investigations revealed for LEDP-M (etoposide, liposomal 
doxorubicin, liposomal cisplatin, mitotane), a liposomal variant of the classical clinical gold-
standard EDP-M (etoposide, doxorubicin, cisplatin, mitotane), enhanced anti-tumoral activity. To 
further increase therapeutic efficacy and improve off-target profiles, this study aimed at the 
investigation of novel liposomal EDP-M regimens in additional preclinical experiments. For this 
purpose, hormonally inactive SW-13 and pediatric SJ-ACC xenografts were utilized. In addition 
to EDP-M and LEDP-M, also a novel therapeutic regimen L(l)EDP-M including liposomal 
etoposide (liposomal etoposide, liposomal doxorubicin, liposomal cisplatin, mitotane) was 
investigated and assessed. Preclinical experiments were performed in short-term and long-term 
settings to investigate anti-tumoral efficacy and side-effects of the different treatment protocols. 
Moreover, the potential of plasma microRNA-210 to be utilized as a therapeutic biomarker was 
evaluated. The novel liposomal regimen demonstrated highest anti-proliferative efficacy against 
SW-13 xenografts, while in SJ-ACC3 tumors only EDP-M was slightly effective. Moreover, 
overall survival was improved in SW-13 tumor bearing mice after treatment with L(l)EDP-M 
compared with controls (p<0.0001) and EDP-M (p=0.003). Elevated circulating microRNA-210 
levels were evident for the LEDP-M responsive SW-13 tumor model, but not for therapy resistant 
SJ-ACC xenografts. Consequently, circulating microRNA-210 could be demonstrated to serve as 
potential biomarker for therapeutic response. Of particular importance for clinical application, 
histological evaluation of hearts and kidneys demonstrated improved toxicity profiles upon 
treatment with liposomal regimens. Following these promising results, a small number of ACC 
patients was treated with a liposomal chemotherapy protocol. Confirming the preclinical results, 
initial clinical data indicate an improved tolerability of liposomal modified EDP-M. In conclusion, 
liposomally modified EDP-M regimens represent promising treatment options which bear the 
potential to improve clinical treatment of ACC in the near future. 
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Zusammenfassung 
Nebennierenrindenkarzinome (NN-Ca) sind sehr seltene und hochmaligne Tumore. Die 
Effektivität systemischer Therapieansätze ist für diese sehr heterogene und aggressive 
Tumorentität oft unbefriedigend und mit starken, dosis-limitierenden Nebenwirkungen 
verbunden. Neue präklinische Ergebnisse zeigen, dass im Vergleich zum klassischen klinischen 
Goldstandard EDP-M (Etoposid, Doxorubicin, Cisplatin, Mitotane) ein liposomal modifiziertes 
Protokoll LEDP-M (Etoposid, liposomales Doxorubicin, liposomales Cisplatin, Mitotane) stärkere 
antitumorale Effekte zeigt. Ziel dieses Projektes war es, die therapeutische Wirksamkeit sowie 
die Nebenwirkungsprofile neuer liposomaler Therapieregime in weiteren präklinischen Studien 
zu untersuchen. Hierfür wurden hormonell inaktive SW-13 Zellen und das pädiatrische SJ-ACC3 
Tumormodell als Xenograftmodelle verwendet. Neben klassischer EDP-M und LEDP-M 
Behandlung wurde ein weiteres liposomales Therapieschema L(l)EDP-M mit liposomalem 
Etoposid untersucht. Die präklinischen Experimente erfolgten in Kurzzeit- und 
Langzeitversuchen, in denen antitumorale Wirksamkeit und das Nebenwirkungsspektrum 
untersucht wurden. Die liposomalen Behandlungsprotokolle zeigten die höchste antitumorale 
Wirksamkeit im SW-13 Tumormodell, während SJ-ACC3 nur schwach auf die klassische EDP-M 
Behandlung ansprach. Zudem erbrachte die Analyse der Überlebensrate im SW-13 Modell eine 
signifikante Verbesserung des Gesamtüberlebens nach L(l)EDP-M Behandlung im Vergleich zu 
Kontrollen (p<0.0001) und klassischem EDP-M Protokoll (p=0.003). Darüber hinaus wurde 
zirkulierende microRNA-210 als potentieller therapeutischer Biomarker für NNR-Ca untersucht.  
Hierbei konnte für zirkulierende microRNA-210 ein Potential als therapeutischer Biomarker 
nachgewiesen werden, welche exklusiv im therapiesensitiven SW-13 Modell nach LEDP-M 
Behandlung signifikant erhöht (p<0.05) war. Die histologische Analyse von Herzen und Nieren 
ergab für die liposomalen Behandlungsprotokolle ein verbessertes Nebenwirkungsprofil 
verglichen mit dem klassischen EDP-M Therapieregime. Erste klinische Daten stützen diese 
Ergebnisse mit einer besseren Verträglichkeit eines liposomalen EDP-M Behandlungsregimes. 
Zusammenfassend stellt ein liposomal modifiziertes EDP-M Behandlungsschema damit eine 
vielversprechende Behandlungsoption für Patienten mit NNR-Ca dar. Ein liposomales EDP-M 
Regime könnte bereits in naher Zukunft in klinische Studien überführt werden und würde die 
Therapie von NNR-Ca vor allem im Bezug auf Verträglichkeit und Behandlungswirksamkeit 
verbessern. 
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7. Appendix 
7.1 Abbreviations 
abbreviation nomenclature 
  
% percentage 
°C celsius 
µg/g microgram per gram 
µg/kg microgram per kilogram 
µl microliter 
µm micrometer 
ab antibody 
ACC adrenocortical carcinoma 
BON BON cell line (human adrenocortical cancer cell line) 
BSA bovine serum albumin 
bw body weight 
cel-miR 39 caenorhabditis elegans microRNA 39 
cm centimeter 
cm2 square centimeter 
cm³ cubic centimeter 
dest. distilled 
DMEM/F12 dulbecco’s modified eagle’s medium 
DU-145 DU-145 cell line (prostate cancer cell line) 
EDP-M etoposide, doxorubicin, cisplatin and mitotane 
EDTA ethylenediaminetetraacetic acid 
ENSAT european network for the study of adrenal tumors 
EPR-effect enhanced permeability and retention effect 
EtOH ethanol 
fig. figure 
FIRM-ACT First International Randomized trial in locally advanced and Metastatic 
Adrenocortical Carcinoma Treatment 
 80 
abbreviation nomenclature 
  
g gram 
g/kg gram per kilogram 
G/L giga per liter 
h hour 
H2O2 hydrogen peroxide 
HCl hydrochloric acid 
HIF-1α hypoxia-inducible factor 1α 
HPF high-power field, 400x magnification, 0.391 mm² 
i.m. intramuscular 
i.p. intraperitoneal 
i.v. intravenous 
IGF2 gene insulin growth factor 2 gene 
ITS insulin-transferrin selenium 
Kelly Kelly cell line (human neuroblastoma cell line) 
kg kilogram 
Ki67 human protein encoded by the MKI67 gene, used as proliferation marker 
l liter 
L(l)EDP-M liposomal etoposide, liposomal doxorubicin, liposomal cisplatin and mitotane 
l/min flow-rate, liter per minute 
LEDP-M etoposide, liposomal doxorubicin, liposomal cisplatin and mitotane 
M molar 
mg milligram 
MgSO4*7H2O magnesiumsulfateheptahydrate 
min. minute 
miR microRNA 
miR-210 microRNA 210 
miR-483-5p microRNA 483-5p 
ml milliliter 
mM millimolar 
MUC-1 MUC-1 xenograft model (adult adrenocortical carcinoma) 
n number 
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abbreviation nomenclature 
  
NaCl sodium chloride 
NaHCO3 Sodium bicarbonate 
NaOH sodium hydroxide 
NCI-H295R NCI-H295R cell line (human adrenocortical cancer cell line) 
nm nanometer 
NMRI nu/nu  NMRI nude mouse strain 
o,p’DDD mitotane (1-(o- chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane) 
P/S penicillin/streptomycin 
PBS phosphate buffered saline 
PEG polyethylene glycol 
PPE palmar-plantar erythrodysesthesia 
qRT-PCR quantitative Real-Time PCR 
r/min rotations per minute 
RNA ribonucleic acid 
RT-qPCR quantitative real-time PCR 
s.c. subcutaneous 
SD standard deviation 
SEM standard error of the mean 
SJ-ACC3 SJ-ACC3 xenograft model (pediatric adrenocortical carcinoma) 
SW-13 
 
SW-13 cell line (human adrenocortical cancer cell line, derived from small-
cell carcinoma of the adrenal gland) 
 
Sz-M streptozotocin, mitotane 
VEGF vascular endothelial growth factor 
vs. versus 
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